Takeda / Friedreich's Ataxia
In 2005, Santhera entered into a licensing and collaboration agreement with Takeda under which Santhera granted Takeda an exclusive license to commercialize CatenaŽ (Takeda's brand name in its territory is SovrimaŽ) in Friedreich's Ataxia in the European Union and Switzerland. Takeda is a leading pharmaceutical company with a well established commercial presence in European markets. Santhera will conduct all clinical development for regulatory approval in Europe and in the US. Santhera in return received an upfront payment of EUR 5 million from Takeda and will receive development milestones and royalties from Takeda.
Takeda / Duchenne Muscular Dystrophy
In 2007, Santhera and Takeda extended their existing commercialization partnership for SovrimaŽ in the European Union and Switzerland to cover the compound's second indication Duchenne Muscular Dystrophy. Santhera will conduct all clinical development for regulatory approval in Europe. Santhera therefore received an upfront payment of EUR 2 million from Takeda and will receive up to EUR 18 million development milestones and royalties once the product is marketed.
In 2007, Santhera and Novartis signed a licensing agreement covering the Novartis compound omigapil (TCH-346). Under this agreement Santhera will develop omigapil as a potential treatment for Congenital Muscular Dystrophy, a severe, genetically determined neuromuscular condition which frequently affects infants or young children with life-threatening progressive muscle weakness. Santhera has the option to expand the development of omigapil into other neuromuscular indications while Novartis retains a buy-back option.